IOVANCE BIOTHERAPEUTICS, INC.IOVAEarnings & Financial Report
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Revenue
$60.0M
Gross Profit
$3.3M
Operating Profit
$-113.8M
Net Profit
$-111.7M
Gross Margin
5.5%
Operating Margin
-189.8%
Net Margin
-186.2%
YoY Growth
92.7%
EPS
$-0.33
IOVANCE BIOTHERAPEUTICS, INC. Q2 FY2025 Financial Summary
IOVANCE BIOTHERAPEUTICS, INC. reported revenue of $60.0M (up 92.7% YoY) for Q2 FY2025, with a net profit of $-111.7M (down 15.0% YoY) (-186.2% margin). Cost of goods sold was $56.7M, operating expenses totaled $117.1M.
Key Financial Metrics
| Total Revenue | $60.0M |
|---|---|
| Net Profit | $-111.7M |
| Gross Margin | 5.5% |
| Operating Margin | -189.8% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
IOVANCE BIOTHERAPEUTICS, INC. Q2 FY2025 revenue of $60.0M breaks down across 2 segments, led by Amtagvi at $54.1M (90.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Amtagvi | $54.1M | 90.2% |
| Proleukin | $5.9M | 9.8% |
IOVANCE BIOTHERAPEUTICS, INC. Revenue by Segment — Quarterly Trend
IOVANCE BIOTHERAPEUTICS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Amtagvi and Proleukin) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Amtagvi | $64.9M | $57.5M | $54.1M | $43.6M |
| Proleukin | $21.9M | $10.0M | $5.9M | $5.8M |
IOVANCE BIOTHERAPEUTICS, INC. Annual Revenue by Year
IOVANCE BIOTHERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $263.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $263.5M |
| 2024 | $164.1M |
IOVANCE BIOTHERAPEUTICS, INC. Quarterly Revenue & Net Profit History
IOVANCE BIOTHERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $86.8M | +17.7% | N/A | N/A |
| Q3 FY2025 | $67.5M | +15.2% | $-91.3M | -135.3% |
| Q2 FY2025 | $60.0M | +92.7% | $-111.7M | -186.2% |
| Q1 FY2025 | $49.3M | +6798.5% | $-116.2M | -235.5% |
| Q4 FY2024 | $73.7M | — | N/A | N/A |
| Q3 FY2024 | $58.6M | +12385.1% | $-83.5M | -142.7% |
| Q2 FY2024 | $31.1M | +12969.7% | $-97.1M | -312.2% |
| Q1 FY2024 | $715.0K | — | $-113.0M | -15800.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $715000 | $31.1M | $58.6M | $73.7M | $49.3M | $60.0M | $67.5M | $86.8M |
| YoY Growth | N/A | 12969.7% | 12385.1% | N/A | 6798.5% | 92.7% | 15.2% | 17.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $869.8M | $964.3M | $991.1M | $910.4M | $966.7M | $907.4M | $904.9M | $913.2M |
| Liabilities | $189.8M | $195.8M | $217.7M | $200.0M | $198.9M | $208.9M | $202.7M | $214.6M |
| Equity | $680.0M | $768.5M | $773.5M | $710.4M | $767.9M | $698.5M | $702.3M | $698.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-122.3M | $-98.4M | $-59.0M | $-73.3M | $-103.7M | $-67.4M | $-78.7M | $-52.6M |